卡介苗初治高危非肌层浸润性膀胱癌的肿瘤学结局:系统综述
该系统综述纳入17项研究,总结卡介苗初治高危非肌层浸润性膀胱癌患者接受卡介苗或替代治疗的肿瘤学结局。卡介苗治疗患者1年无复发生存率为66-96%,替代治疗为51-99%;但研究异质性和样本量小限制结论,12项临床试验正在进行。
要点
- 卡介苗治疗高危NMIBC的5年无复发生存率为39-66%,无进展生存率为70-84%。
- 替代治疗(免疫检查点抑制剂、化疗联合、新型膀胱内治疗)1年无复发生存率51-99%,5年47-55%。
- 卡介苗和替代治疗的不良事件发生率研究间差异大,需进一步验证替代治疗。
核心结论
- 卡介苗初治高危NMIBC的替代治疗正在涌现,但需进一步验证。
- 毒性、成本和长期疗效等挑战持续存在,正在进行的试验结果将决定其未来临床角色。
研究设计与样本
- 系统综述,检索MEDLINE、EMBASE、Scopus、Web of Science和Cochrane Library,共检索1042项研究,最终纳入17项符合标准的研究。
- 遵循PRISMA指南,PROSPERO注册号CRD42024564900。
主要发现
- 12项卡介苗治疗研究(n=1418)中,1年无复发生存率66-96%,2年63-96%,5年39-66%。
- 卡介苗治疗患者1年无进展生存率81-98%,2年70-96%,5年70-84%。
- 9项替代治疗研究(n=657)中,1年无复发生存率51-99%,2年48-88%,5年47-55%。
- 替代治疗患者1年无进展生存率90-100%,2年88-96%,5年84-93%。
- 卡介苗和替代治疗的不良事件发生率在研究间差异广泛。
关键数值与推荐
- 卡介苗治疗患者1年无复发生存率66-96%,2年63-96%,5年39-66%。
- 卡介苗治疗患者1年无进展生存率81-98%,2年70-96%,5年70-84%。
- 替代治疗患者1年无复发生存率51-99%,2年48-88%,5年47-55%。
- 替代治疗患者1年无进展生存率90-100%,2年88-96%,5年84-93%。
临床怎么用
- 卡介苗仍是高危NMIBC的标准治疗,但不良事件、疗效有限和短缺影响完成率。
- 替代治疗包括免疫检查点抑制剂、化疗联合和新型膀胱内治疗,需进一步验证。
局限性
- 研究异质性和样本量小限制统计学意义的结论。
- 不良事件发生率研究间差异大。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND OBJECTIVE: Bacillus Calmette-Guérin (BCG) is the standard treatment in patients harboring high-risk (HR) non-muscle-invasive bladder cancer (NMIBC). However, BCG therapy faces frequent adverse events (AEs), limited efficacy, and ongoing shortages, leading to a low completion rate, access challenges, and high recurrence. In consequence, there is a growing interest in exploring alternative treatments, including immune checkpoint inhibitors, chemotherapy combinations, and novel intravesical therapies. This systematic review summarizes current prospective evidence on BCG and alternative treatment options for BCG-naïve HR-NMIBC patients (PROSPERO: CRD42024564900). METHODS: A systematic search in MEDLINE, EMBASE, Scopus, Web of Science, and Cochrane Library retrieved 1042 studies, of which 17 met the inclusion criteria (following the Preferred Reporting Items for Systematic Reviews and Meta-analyses guidelines). KEY FINDINGS AND LIMITATIONS: In 12 studies on BCG-treated patients (n = 1418), recurrence-free survival (RFS) rates were 66-96% at 1-yr, 63-96% at 2-yr, and 39-66% at 5-yr follow-up. Progression-free survival (PFS) rates were 81-98% at 1-yr, 70-96% at 2-yr, and 70-84% at 5-yr follow-up. In nine studies focusing on patients treated with alternative strategies (n = 657), RFS rates were 51-99% at 1-yr, 48-88% at 2-yr, and 47-55% at 5-yr follow-up. PFS was 90-100% at 1-yr, 88-96% at 2-yr, and 84-93% at 5-yr follow-up. AE rates varied widely across studies, for both BCG and alternative treatments. Unfortunately, studies heterogeneity and a small sample sizes limit statistically meaningful conclusions. Twelve clinical trials are currently investigating new strategies for BCG-naïve HR NMIBC patients. CONCLUSIONS AND CLINICAL IMPLICATIONS: Alternative therapies for BCG-naïve HR NMIBC patients are emerging but need further validation. As challenges such as toxicity, cost, and long-term efficacy persist, ongoing trial results will be crucial in determining their role in future clinical practice.
引用
- Longoni M, Scilipoti P, Soria F, et al. Oncological Outcomes in Bacillus Calmette-Guérin-naïve High-risk Non-muscle-invasive Bladder Cancer Patients: A Systematic Review on Current Treatment Strategies and Future Perspectives. Eur Urol Oncol. 2025. PMID: 40204534. doi:10.1016/j.euo.2025.03.007
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。